Jazz Pharmaceuticals plc
JAZZNext catalyst
Cannabidiol
Sturge-Weber Syndrome
Get an email about JAZZ's next catalysts
Track Jazz Pharmaceuticals (JAZZ) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 5 more upcoming events in our data (conference, Phase 2 readout, Phase 3 readout).See the timeline
6 upcoming, 1 past
Conference Presentation
ET. The article text is truncated and other conferences (e.g., Piper) are not fully detailed.
SourceCPX-351 Phase 2 Est. Readout
Estimated primary completion for CPX-351 trial (NCT04990102) in Acute Myeloid Leukemia (AML) in Remission. Topline data typically follows completion by weeks to months.
SourceDefibrotide Phase 2 Est. Readout
Estimated primary completion for Defibrotide trial (NCT04652115) in Covid19. Topline data typically follows completion by weeks to months.
SourceZanidatamab Phase 2 Est. Readout
Primary completion for Zanidatamab trial (NCT06695845) in Breast Cancer
SourceFDA PDUFA Date oral cannabidiol capsule
NDA filing. Extracted from SEC filing: EX-99.1
SourceCPX-351 Phase 3 Est. Readout
Estimated primary completion for CPX-351 trial (NCT03897127) in Acute Myeloid Leukemia. Topline data typically follows completion by weeks to months.
SourceUpcoming FDA decisions
How JAZZ's past catalysts played out
Market Overview
Stock performance and key metrics
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
WebsiteXyrem (sodium oxybate) oral solution
Fibromyalgia
Xyrem
Narcolepsy With Cataplexy
Dordaviprone (ONC201)
H3 K27M
Sodium Oxybate
Essential Tremor
IM JZP-458
Acute Lymphoblastic Leukemia
a benzodiazepine drug
Anxiety Disorder
JZP-258
Idiopathic Hypersomnia
Nabiximols
Pain
THC Alone
Palliative Care
GW-1000-02
Pain
Modafinil at established dose
Narcolepsy
Sodium Oxybate & 6 Tablets
Fibromyalgia
ONC201
Diffuse Intrinsic Pontine Glioma
JZP926 capsule
Juvenile Myoclonic Epilepsy
Zanidatamab
HER2-positive Breast Cancer
Sativex®
Spasticity
JZP-110
Obstructive Sleep Apnea
Brincidofovir
Adenovirus Infection
Xywav
Narcolepsy
GWP42003-P
Epilepsy
CPX-351
Acute Myeloid Leukemia (AML)
7+3 (cytarabine and daunorubicin)
High Risk Acute Myeloid Leukemia
Xyrem®
Fibromyalgia
Defibrotide
Severe Hepatic Veno-Occlusive Disease
IV JZP-458
Acute Lymphoblastic Leukemia
experimental anti-anxiety drug
Anxiety Disorder
Sativex
Multiple Sclerosis
GW-2000-02
Pain
Sodium Oxybate Oral Solution (6 grams)
Fibromyalgia
Vyxeos
Acute Myeloid Leukaemia
Custodiol
Coronary Artery Stenosis
Sodium Oxybate & 8 Tablets
Fibromyalgia
Busulphan
Acute Myeloid Leukaemia
CPX-315
Acute Myeloid Leukemia
TTX-MC138
HER2-positive Breast Cancer
Liposome-encapsulated Daunorubicin-Cytarabine
Recurrent Acute Myeloid Leukemia
Dociparstat sodium
Acute Myeloid Leukemia
Suvecaltamide
Parkinson Disease
Lurbinectedin
Refractory Ewing Sarcoma
GWP42006
Epilepsy
ZW25 (Zanidatamab)
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Recombinant Granulocyte Colony-Stimulating Factor
Acute Myeloid Leukemia
GWP42003
Schizophrenia
Evorpacept
HER2-expressing Cancers
GWP42004
Dyslipidemias
JZP385
Essential Tremor
Intensive Salvage Therapy
Acute Myeloid Leukemia
ONC206: Dose 1
Advanced Pheochromocytoma and Paraganglioma
ONC206: Dose 2
Advanced Pheochromocytoma and Paraganglioma
Clobazam
Epilepsy
DNX-2401
Diffuse Intrinsic Pontine Glioma
Clonazepam
Epilepsy
Daunorubicin
Acute Myeloid Leukemia
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Colorectal Neoplasms
CX-8998
Epilepsy
JZP150
Post Traumatic Stress Disorder
ADX-N05
Narcolepsy
asparaginase Erwinia chrysanthemi
Acute Lymphoblastic Leukemia
ONC206
Advanced Pheochromocytoma and Paraganglioma
mFOLFOX
Gastroesophageal Adenocarcinoma
Cytarabine and Idarubicin
Acute Myeloid Leukemia
Cannabidivarin
Autism Spectrum Disorder
CBD Oral Solution
Fragile X Syndrome
Bicarbonate de sodium
Hematologic Disease
Glasdegib
Acute Myelogenous Leukemia (AML) Due to Therapy
Cannabidiol
Sturge-Weber Syndrome
Epidiolex
Sturge - Weber Syndrome (SWS)
Enasidenib Mesylate
Recurrent Acute Myeloid Leukemia
MHA
Myeloid Neoplasm
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Xyrem (sodium oxybate) oral solution | Phase 3 | Fibromyalgia | - | - |
Xyrem | Phase 3 | Narcolepsy With Cataplexy | - | - |
Dordaviprone (ONC201) | Phase 3 | H3 K27M | - | - |
Sodium Oxybate | Phase 3 | Essential Tremor | - | - |
IM JZP-458 | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
a benzodiazepine drug | Phase 3 | Anxiety Disorder | - | - |
JZP-258 | Phase 3 | Idiopathic Hypersomnia | - | - |
Nabiximols | Phase 3 | Pain | - | - |
THC Alone | Phase 3 | Palliative Care | - | - |
GW-1000-02 | Phase 3 | Pain | - | - |
Modafinil at established dose | Phase 3 | Narcolepsy | - | - |
Sodium Oxybate & 6 Tablets | Phase 3 | Fibromyalgia | - | - |
ONC201 | Phase 3 | Diffuse Intrinsic Pontine Glioma | - | - |
JZP926 capsule | Phase 3 | Juvenile Myoclonic Epilepsy | - | - |
Zanidatamab | Phase 3 | HER2-positive Breast Cancer | - | - |
Sativex® | Phase 3 | Spasticity | - | - |
JZP-110 | Phase 3 | Obstructive Sleep Apnea | - | - |
Brincidofovir | Phase 3 | Adenovirus Infection | - | - |
Xywav | Phase 3 | Narcolepsy | - | - |
GWP42003-P | Phase 3 | Epilepsy | - | - |
CPX-351 | Phase 3 | Acute Myeloid Leukemia (AML) | - | - |
7+3 (cytarabine and daunorubicin) | Phase 3 | High Risk Acute Myeloid Leukemia | - | - |
Xyrem® | Phase 3 | Fibromyalgia | - | - |
Defibrotide | Phase 3 | Severe Hepatic Veno-Occlusive Disease | - | - |
IV JZP-458 | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
experimental anti-anxiety drug | Phase 3 | Anxiety Disorder | - | - |
Sativex | Phase 3 | Multiple Sclerosis | - | - |
GW-2000-02 | Phase 3 | Pain | - | - |
Sodium Oxybate Oral Solution (6 grams) | Phase 3 | Fibromyalgia | - | - |
Vyxeos | Phase 3 | Acute Myeloid Leukaemia | - | - |
Custodiol | Phase 3 | Coronary Artery Stenosis | - | - |
Sodium Oxybate & 8 Tablets | Phase 3 | Fibromyalgia | - | - |
Busulphan | Phase 3 | Acute Myeloid Leukaemia | - | - |
CPX-315 | Phase 2 | Acute Myeloid Leukemia | - | - |
TTX-MC138 | Phase 2 | HER2-positive Breast Cancer | - | - |
Liposome-encapsulated Daunorubicin-Cytarabine | Phase 2 | Recurrent Acute Myeloid Leukemia | - | - |
Dociparstat sodium | Phase 2 | Acute Myeloid Leukemia | - | - |
Suvecaltamide | Phase 2 | Parkinson Disease | - | - |
Lurbinectedin | Phase 2 | Refractory Ewing Sarcoma | - | - |
GWP42006 | Phase 2 | Epilepsy | - | - |
ZW25 (Zanidatamab) | Phase 2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | - | - |
Recombinant Granulocyte Colony-Stimulating Factor | Phase 2 | Acute Myeloid Leukemia | - | - |
GWP42003 | Phase 2 | Schizophrenia | - | - |
Evorpacept | Phase 2 | HER2-expressing Cancers | - | - |
GWP42004 | Phase 2 | Dyslipidemias | - | - |
JZP385 | Phase 2 | Essential Tremor | - | - |
Intensive Salvage Therapy | Phase 2 | Acute Myeloid Leukemia | - | - |
ONC206: Dose 1 | Phase 2 | Advanced Pheochromocytoma and Paraganglioma | - | - |
ONC206: Dose 2 | Phase 2 | Advanced Pheochromocytoma and Paraganglioma | - | - |
Clobazam | Phase 2 | Epilepsy | - | - |
DNX-2401 | Phase 2 | Diffuse Intrinsic Pontine Glioma | - | - |
Clonazepam | Phase 2 | Epilepsy | - | - |
Daunorubicin | Phase 2 | Acute Myeloid Leukemia | - | - |
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection | Phase 2 | Colorectal Neoplasms | - | - |
CX-8998 | Phase 2 | Epilepsy | - | - |
JZP150 | Phase 2 | Post Traumatic Stress Disorder | - | - |
ADX-N05 | Phase 2 | Narcolepsy | - | - |
asparaginase Erwinia chrysanthemi | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
ONC206 | Phase 2 | Advanced Pheochromocytoma and Paraganglioma | - | - |
mFOLFOX | Phase 2 | Gastroesophageal Adenocarcinoma | - | - |
Cytarabine and Idarubicin | Phase 2 | Acute Myeloid Leukemia | - | - |
Cannabidivarin | Phase 2 | Autism Spectrum Disorder | - | - |
CBD Oral Solution | Phase 2 | Fragile X Syndrome | - | - |
Bicarbonate de sodium | Phase 2 | Hematologic Disease | - | - |
Glasdegib | Phase 2 | Acute Myelogenous Leukemia (AML) Due to Therapy | - | - |
Cannabidiol | Phase 2 | Sturge-Weber Syndrome | - | - |
Epidiolex | Phase 2 | Sturge - Weber Syndrome (SWS) | - | - |
Enasidenib Mesylate | Phase 2 | Recurrent Acute Myeloid Leukemia | - | - |
MHA | Phase 2 | Myeloid Neoplasm | - | - |
Epilepsy
3 drugs in this indication
Refractory Ewing Sarcoma
1 drug in this indication
Multiple Sclerosis
1 drug in this indication
HER2-positive cancer
1 drug in this indication
Pain
1 drug in this indication
Parkinson Disease
1 drug in this indication
Spasticity
1 drug in this indication
Narcolepsy With Cataplexy
1 drug in this indication
First-line HER2-positive advanced gastroesophageal adenocarcinoma (GEA)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Jazz Pharmaceuticals plc's drug pipeline?→
CatalystAlert tracks 69 drug candidates in Jazz Pharmaceuticals plc's (JAZZ) pipeline across Phase 3, Phase 2. Its lead program is Cannabidiol (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Jazz Pharmaceuticals plc's next FDA catalyst?→
Jazz Pharmaceuticals plc's (JAZZ) next tracked catalyst is a PDUFA date expected Apr 16, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JAZZ biotech catalysts?→
Add JAZZ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Jazz Pharmaceuticals plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
